261 related articles for article (PubMed ID: 7915067)
41. [Effects of the K(+) channel blocker tedisamil on hemodynamics, myocardial ischemia and neurohumoral systems in patients with stable angina pectoris. A comparison with the beta blocker atenolol].
Mitrovic V; Miskovic A; Straub M; Beckmann K; Thormann J; Pitschner H
Z Kardiol; 1999 Oct; 88(10):838-49. PubMed ID: 10552188
[TBL] [Abstract][Full Text] [Related]
42. [Gallopamil infusion for treatment of Prinzmetal angina].
Carlon R; Cappelletti F; Ometto R; Maiolino P; Vincenzi M
Cardiologia; 1990 May; 35(5):407-14. PubMed ID: 2125241
[TBL] [Abstract][Full Text] [Related]
43. Hemodynamic actions on alinidine during exercise in patients with coronary artery disease.
Löllgen H; Just H; Wollschläger H; Kersting F
Z Kardiol; 1981 May; 70(5):425-8. PubMed ID: 7269729
[TBL] [Abstract][Full Text] [Related]
44. Hemodynamic effects of the calcium channel blocker pranidipine on exercise-induced angina.
Nishinaka Y; Yokota M; Watanabe M; Sobue T; Iwase M; Ukai M; Ando A; Nagata K; Saito H
Int J Clin Pharmacol Ther; 1994 Oct; 32(10):542-9. PubMed ID: 7834162
[TBL] [Abstract][Full Text] [Related]
45. [The new potassium channel blocker tedisamil and its hemodynamic, anti-ischemic and neurohumoral effect in patients with coronary heart disease].
Mitrovic V; Oehm E; Strasser R; Schlepper M; Pitschner HF
Z Kardiol; 1996 Dec; 85(12):961-72. PubMed ID: 9082675
[TBL] [Abstract][Full Text] [Related]
46. Multifactorial actions of beta-adrenergic blocking drugs in ischemic heart disease: current concepts.
Frishman WH
Circulation; 1983 Jun; 67(6 Pt 2):I11-8. PubMed ID: 6133640
[TBL] [Abstract][Full Text] [Related]
47. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.
Barbier GH; Shettigar UR; Appunn DO
Int J Clin Pharmacol Ther; 1995 Apr; 33(4):212-8. PubMed ID: 7620691
[TBL] [Abstract][Full Text] [Related]
48. Atrial natriuretic peptide attenuates pacing-induced myocardial ischemia during general anesthesia in patients with coronary artery disease.
Valsson F; Lundin S; Kirnö K; Hedner T; Houltz E; Saito Y; Ricksten SE
Anesth Analg; 1999 Feb; 88(2):279-85. PubMed ID: 9972741
[TBL] [Abstract][Full Text] [Related]
49. Symptomatic and hemodynamic recovery following dobutamine stress echo: benefit of low-dose esmolol administration.
Abdullah EE; Pollick C
Int J Card Imaging; 1997 Feb; 13(1):53-7. PubMed ID: 9080239
[TBL] [Abstract][Full Text] [Related]
50. [Characteristics and clinical use of esmolol].
Ravussin P
Minerva Anestesiol; 1992 Apr; 58(4 Suppl 1):77-9. PubMed ID: 1352393
[TBL] [Abstract][Full Text] [Related]
51. Use of an ultrashort-acting beta-receptor blocker (esmolol) in patients with acute myocardial ischemia and relative contraindications to beta-blockade therapy.
Kirshenbaum JM; Kloner RF; McGowan N; Antman EM
J Am Coll Cardiol; 1988 Sep; 12(3):773-80. PubMed ID: 2900259
[TBL] [Abstract][Full Text] [Related]
52. [Effects of gallopamil on coronary blood flow and vasomotility].
Bortone A; Chiddo A; Quagliara D; Musci S; Troito G; Lafranceschina C; Gaglione A; Rizzon P
Cardiologia; 1990 Jun; 35(6):479-84. PubMed ID: 2078839
[TBL] [Abstract][Full Text] [Related]
53. [Hemodynamic effects of intravenously administered celiprolol in patient with coronary heart disease and depressed left ventricular function].
Leisch F; Herbinger W
Arzneimittelforschung; 1987 Apr; 37(4):444-6. PubMed ID: 2886131
[TBL] [Abstract][Full Text] [Related]
54. Intravenous esmolol is well tolerated in elderly patients with heart failure in the early phase of non-ST elevation myocardial infarction.
Koutouzis M; Nikolidakis S; Grigoriadis A; Koutsogeorgis D; Kyriakides ZS
Drugs Aging; 2006; 23(8):673-80. PubMed ID: 16964989
[TBL] [Abstract][Full Text] [Related]
55. The use of esmolol in whole-body hyperthermia: cardiovascular effects.
Berry JM; Michalsen A; Nagle V; Bull JM
Int J Hyperthermia; 1997; 13(3):261-8. PubMed ID: 9222810
[TBL] [Abstract][Full Text] [Related]
56. Acute systemic and antiischemic effects of epanolol in patients with coronary artery disease.
Venneker EH; Remme WJ; van Hoogenhuyze DC; Krauss XH; Bartels GL; Kruijssen DA; Storm CJ; van Schelven D
Cardiovasc Drugs Ther; 1994 Apr; 8(2):211-9. PubMed ID: 7918133
[TBL] [Abstract][Full Text] [Related]
57. Hemodynamic, antiischemic, and neurohumoral effects of enoximone in patients with coronary artery disease.
Mitrovic V; Thormann J; Neuzner J; Bahawar H; Volz M; Dieterich HA; Schlepper M
Am Heart J; 1989 Jan; 117(1):106-11. PubMed ID: 2563185
[TBL] [Abstract][Full Text] [Related]
58. Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia.
Sung RJ; Blanski L; Kirshenbaum J; MacCosbe P; Turlapaty P; Laddu AR
J Clin Pharmacol; 1986 Mar; 26(S1):A15-A26. PubMed ID: 2870082
[TBL] [Abstract][Full Text] [Related]
59. [Multicenter long-term study of gallopamil in patients with coronary heart disease].
Sućić M; Schiemann J
Arzneimittelforschung; 1984; 34(11):1587-94. PubMed ID: 6543136
[TBL] [Abstract][Full Text] [Related]
60. Effects of esmolol on cardiac function: evaluation by noninvasive techniques.
Iskandrian AS; Hakki AH; Laddu A
Am J Cardiol; 1985 Oct; 56(11):27F-32F. PubMed ID: 2864845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
